- Home
- CRK vs LEGN Comparison
CRK vs LEGN Comparison
Compare CRK & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRK | LEGN |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRK | LEGN |
|---|---|---|
| Price | $19.09 | $18.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 14 |
| Target Price | $22.30 | ★ $63.46 |
| AVG Volume (30 Days) | 3.0M | ★ 3.2M |
| Earning Date | 02-11-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.36 | N/A |
| Revenue | ★ $2,220,289,000.00 | $909,045,000.00 |
| Revenue This Year | $3.46 | $67.56 |
| Revenue Next Year | $7.84 | $45.77 |
| P/E Ratio | $14.10 | ★ N/A |
| Revenue Growth | ★ 76.99 | 74.75 |
| 52 Week Low | $14.65 | $16.24 |
| 52 Week High | $31.17 | $45.30 |
Technical Indicators
Market Signals| Indicator | CRK | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 35.60 | 40.59 |
| Support Level | $20.60 | $16.82 |
| Resistance Level | $23.23 | $17.38 |
| Average True Range (ATR) | 1.16 | 0.78 |
| MACD | -0.36 | 0.23 |
| Stochastic Oscillator | 3.56 | 60.53 |
Price Performance
Historical ComparisonAbout CRK Comstock Resources Inc.
Comstock Resources Inc is an independent natural gas producer operating in the Haynesville shale, a natural gas basin located in North Louisiana and East Texas with superior economics given its geographical proximity to the Gulf Coast natural gas markets. The Company operates in one business segment, the exploration and production of North American natural gas and oil. It is engaged in the acquisition, development, production, and exploration of oil and natural gas. Its oil and gas operations are concentrated in Louisiana and Texas.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.